Journal of Nanomedicine & Nanotechnology

Outcome of nanostructured bioidentical hormone therapy in climacteric syndrome patients: A 5 years clinical study follow-up

International Conference and Exhibition on Nanotechnology & Nanomedicine

March 12-14, 2012 Omaha Marriott, USA

Marco Botelho, Wagner Gonzaga, Dinalva Queiroz, Gisele Barros, S?nia Mendes, S?mela Soraya Gomes de Oliveira, Aar?o Lyra and Paul Ling Tai

Accepted Abstracts: J Nanomedic Nanotechnol

Abstract:

Hormonal replacement therapy (HRT) has been used for the treatment of climacteric syndrome (CS); however, little is known concerning the use of Nanostructured Transdermal Bioidentical Compauded Hormones (NTBH). Side effects are dependent on dose and route of administration and that is why, new hormonal treatment modalities are being developed. One hundred twenty-two women, were diagnosed with CS, were selected and followed for 5 years and were treated with NTBH between April 2003 and December 2008. All patients were followed prospectively based on a pre-defined protocol that included evaluation of clinical parameters such as bilateral mammogram (Breast Imaging Reporting/Data System-BIRADS), blood pressure, estradiol, body weight, and follicular hormone stimulation (FSH), testing at 3, 6, 12 months, and then yearly. The mean age was 56.8 ? 6.27 years old. There were a drop out of 22 subjects, and a total of 100 patients completed the study and were treated with NTBH. The mean of follow-up was 61.2 months during which time 46% of the individuals the BIRADS classification was not altered and in 15% there was observed a positive changed in BIRADS classification, and finally in 22% was noted a increased in BIRADS classification however none of them was classified as BIRADS 4 or 5 levels. It was observed a significant increased in estradiol levels and in other hand the opposite observation in FSH levels. Based on our early experience, we believe that NTBH should be considered in treating patients with climacteric syndrome (CS)

Biography :

Marco Botelho has completed his Ph.D at the age of 39 years from Federal University and postdoctoral studies from Michigan University School of Dentistry. He is a Coordinator of the PhD Program RENORBIO at Potiguar University. He is also the Scientific Director of Evidence Group, a Brazilian Institute for Biomedical Research, a Biopharmaceutical service organization. He has published more than 16 papers in reputed journals and serving as an editorial board member of repute and a Scientific AD HOC Consulting for Brazilian Agency for Research (CNPq)